We designed a cascade spiral microfluidic device (i-Finity®)continuously isolated the unlabeled cancer cells from blood samples without lysing processes. The results showed that the i-Finity® device excluded a high percentage of RBCs in the first stagerecollected the cancer cells in the second stage. The i-Finity® device can efficiently enrich the cancer cells more than 1000 times in 10 minutes, which substantially curtailed sample preparation timeimproved the accuracy of diagnosis.

Here, we introduce an electricity-free centrifuge platform based on a manual centrifuge. The provided centrifugal force is sufficient to produce a plasma purity of 99 separated in as little as 2−3 min. We then performed an immunoassay on a paper devicethe results were observed by a portable reader. As a result, the detection limit of the C-Reactive Protein is 1 ng/mL, with a total turnaround time of 7 min.

Monitoring PCDM-specific biomarkers, galectin-3S100A9, to serve as a risk assessment of pancreatic cancer on new-onset diabetes patients for early detection of PC.

Our technology combines optimized semiconductor manufacturing technique with unique biomediator preparation to achieve the first reliable POC biosensing platform. Sensors developed according to this method possess reproducibility, accuracy,stability that meet POC. Our sensors are portable, require low sample volume, do not require sample processing,are extremely suitable for use in POC settings. They can also be integrated into IoT systems to aide in rapid decision making,can be mass produced. Overall, we are the first to achieve accessible, reliable detection at the POC.